Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Atai Life Sciences unit GABA Therapeutics upbeat about deuterated form of 1960s drug

By Brian Buntz | January 9, 2023

Atai Life SciencesThe biopharma Atai Life Sciences (Nasdaq:ATAI) subsidiary GABA Therapeutics is sharing positive results from a Phase 1 study of GRX-917, a deuterated form of etifoxine, which the German firm Hoechst developed in the 1960s. Sanofi-Aventis eventually subsumed Hoechst in 2004.

Atai investigated the safety, tolerability and pharmacokinetic profile of orally administered GRX-917 in a Phase 1 study.

The company is developing GRX-917 for generalized anxiety disorder (GAD).

An improved safety profile than benzodiazepines?

The company believes the GRX-917 could have a better safety profile than traditional benzodiazepines.

“Based on etifoxine’s safety and efficacy profile, we believe GRX-917 will offer a differentiated treatment for GAD with fewer side effects—such as sedation, respiratory depression, and withdrawal,” said Dr. Mario Saltarelli, chief medical officer of GABA Therapeutics.

The company noted that the drug candidate was well tolerated.

Investigators noticed adverse events in 53% (17/32) recipients of GRX-917 in the single-ascending dose (SAD) trial portion. In addition, they noticed that 50% (5/10) of placebo recipients had adverse events.

Overall, compared to the placebo, GRX-917 was well-tolerated and neither dose-related, nor dose-limiting adverse events were observed. There were no serious adverse events reported nor discontinuations due to drug administration. Furthermore, in contrast to current first-line anxiety disorder treatments such as benzodiazepines, sedation was found to be comparable to placebo.

Etifoxine currently remains in limited use

The drug, which has the trade name Stresam, is currently available in several markets, including in the European Union. Early last year, EU regulators decided that etifoxine could be used for anxiety disorders but not in “patients who previously had severe skin reactions or severe liver problems” after taking the drug.

GABA Therapeutics notes on its website that the original form of the drug was never introduced in the U.S. Hoechst eventually sold the rights to the drug.

GABA claims that GRX-917 is a patented “vastly improved variant of etifoxine.”

Etifoxine has been off-patent since 1979.

Last month, another Atai subsidiary, Kures, announced inconclusive data regarding the impact of the kratom-derived compound KUR-101 on respiration in a Phase 1 study. Its stock dipped about 9% to $2.77.

Since then, Atai’s share price has continued to slide, recently falling about 6% to $1.71.


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: Atai Life Sciences
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE